Pre-exposure rabies prophylaxis: A systematic review;Prophylaxie pré-exposition à la rage: Un examen systématique;Profilaxis pre exposición a la rabia: Una revisión sistemática

Bulletin of the World Health Organization

Volumn 95, Issue 3, 2017, Pages 210-219

  Kessels, Jocelyn A ^a   Recuenco, Sergio ^b   Vela, Ana Maria Navarro ^c   Deray, Raffy ^d   Vigilato, Marco ^e   Ertl, Hildegund ^f   Durrheim, David ^g   Rees, Helen ^h   Nel, Louis H ⁱ   Abela Ridder, Bernadette ^j   Briggs, Deborah ^k  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSTITUTO NACIONAL DE SALUD   (Peru)

^c MINISTERIO DE SALUD   (Peru)

^d Environmental and Occupational Health Office   (Philippines)

^e Veterinary Public Health Rio de Janeiro   (Brazil)

^f WISTAR INSTITUTE   (United States)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF PRETORIA   (South Africa)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k KANSAS STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE;

ADULT; COST; COST ANALYSIS; DATABASE; ENCEPHALITIS; HEALTH EDUCATION; HEALTH RISK; HEALTH SURVEY; IMMUNITY; RABIES; SAFETY; VACCINE;

ANTIBODY TITER; COST EFFECTIVENESS ANALYSIS; DOG BITE; DRUG SAFETY; ENDEMIC DISEASE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PERU; PHILIPPINES; POST EXPOSURE PROPHYLAXIS; POVERTY; PRE-EXPOSURE PROPHYLAXIS; PUBLIC HEALTH CAMPAIGN; RABIES; REVIEW; SYSTEMATIC REVIEW; VACCINATION; VAMPIRE BAT; AGE; ANIMAL; BAT; BITES AND STINGS; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DOG; ECONOMICS; HEALTH SERVICE; PREVENTIVE HEALTH SERVICE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UTILIZATION; VIROLOGY;

PERU; PHILIPPINES;

ANIMALIA; JAPANESE ENCEPHALITIS VIRUS;

AGE FACTORS; ANIMALS; BITES AND STINGS; CHIROPTERA; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DOGS; HEALTH SERVICES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MODELS, ECONOMETRIC; PERU; PHILIPPINES; RABIES VACCINES; RISK FACTORS; TIME FACTORS;

EID: 85014614985     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.16.173039     Document Type: Review

References (49)

1. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al.; Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015 Apr;9(4):e0003709 doi:http://dx.doi.org/10.1371/journal.pntd.0003709 PMID: 25881058
2. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005 May;83(5):360-8. PMID: 15976877
3. Crowcroft NS, Thampi N. The prevention and management of rabies. BMJ. 2015;350:g7827. PMID: 25589091
4. Dodet B, Durrheim DN, Rees H. Rabies: underused vaccines, unnecessary deaths. Vaccine. 2014 Apr 11;32(18):2017-9 doi:http://dx.doi.org/10.1016/j.vaccine.2013.12.031 PMID: 24434045
5. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec. 2010 Aug 6;85(32):309-20.
6. Estrategia nacional de zoonosis-MINSA. Informe 37-2015. Resultados plan de vacunacion antirrabica de pre-exposicion en comunidades en riesgo de rabia de la Region Amazonas: Peru 2011-2014. Lima: Ministerio de Salud del Peru; 2014. Spanish.doi:http://dx.doi.org/10.1016/j.vaccine.2010.02.093 PMID: 20211220
7. Dodet B; Asian Rabies Expert Bureau (AREB). Report of the sixth AREB meeting, Manila, The Philippines, 10-12 November 2009. Vaccine. 2010 Apr 26;28(19):3265-8 doi:http://dx.doi.org/10.1016/j.vaccine.2010.02.093 PMID: 20211220
8. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 doi:http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00135 PMID: 19622511
9. Gilbert AT, Petersen BW, Recuenco S, Niezgoda M, Gomez J, Laguna-Torres VA, et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am J Trop Med Hyg. 2012 Aug;87(2):206-15 doi:http://dx.doi.org/10.4269/ajtmh.2012.11-0689 PMID: 22855749
10. Schneider MC, Aron J, Santos-Burgoa C, Uieda W, Ruiz-Velazco S. Common vampire bat attacks on humans in a village of the Amazon region of Brazil. Cad Saude Publica. 2001 Nov-Dec;17(6):1531-6 doi:http://dx.doi.org/10.1590/S0102-311X2001000600038 PMID: 11784915
11. Streicker DG, Recuenco S, Valderrama W, Gomez Benavides J, Vargas I, Pacheco V, et al. Ecological and anthropogenic drivers of rabies exposure in vampire bats: implications for transmission and control. Proc Biol Sci. 2012 Sep 7;279(1742):3384-92 doi:http://dx.doi.org/10.1098/rspb.2012.0538 PMID: 22696521
12. National rabies prevention and control program. Manual of operations (2012). Manila: Department of Health, Philippines;2012. Available from: http://www.doh.gov.ph/sites/default/files/publications/FINALMOP6.4.13WORDRADMay30.pdf [cited 2016 Nov 18].
13. Aikimbayev A, Briggs D, Coltan G, Dodet B, Farahtaj F, Imnadze P, et al. Fighting rabies in Eastern Europe, the Middle East and Central Asia-experts call for a regional initiative for rabies elimination. Zoonoses Public Health. 2014 May;61(3):219-26 doi:http://dx.doi.org/10.1111/zph.12060 PMID: 23782901
14. Banga N, Guss P, Banga A, Rosenman KD. Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine. 2014 Feb 12;32(8):979-83 doi:http://dx.doi.org/10.1016/j.vaccine.2013.12.019 PMID: 24394442
15. Brown D, Fooks AR, Schweiger M. Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels. Adv Prev Med. 2011;2011:601789 doi:http://dx.doi.org/10.4061/2011/601789 PMID: 21991440
16. Brown D, Featherstone JJ, Fooks AR, Gettner S, Lloyd E, Schweiger M. Intradermal pre-exposure rabies vaccine elicits long lasting immunity. Vaccine. 2008 Jul 23;26(31):3909-12 doi:http://dx.doi.org/10.1016/j.vaccine.2008.04.081 PMID: 18547689
17. Chulasugandha P, Khawplod P, Havanond P, Wilde H. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine. 2006 Feb 27;24(9):1478-82 doi:http://dx.doi.org/10.1016/j.vaccine.2005.03.059 PMID: 16221511
18. Cunha RS, Silva de A C, Batista AM, Chaves LB, Barata RB. Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring. Rev Saude Publica. 2010 Jun;44(3):548-54 doi:http://dx.doi.org/10.1590/S0034-89102010005000005 PMID: 20464263
19. Dodet B, Asian Rabies Expert B; Asian Rabies Expert Bureau (AREB). Report of the Fifth AREB Meeting Ho Chi Minh City, Vietnam, 17-20 November 2008. Vaccine. 2009 Apr 21;27(18):2403-7 doi:http://dx.doi.org/10.1016/j.vaccine.2009.02.012 PMID: 19368779
20. Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, et al. Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine. Travel Med Infect Dis. 2015 May-Jun;13(3):241-50 doi:http://dx.doi.org/10.1016/j.tmaid.2015.05.008 PMID: 26005163
21. Kamoltham T, Thinyounyong W, Khawplod P, Phraisuwan P, Phongchamnaphai P, Anders G, et al. Immunogenicity of simulated PCECV postexposure booster doses 1, 3, and 5 years after 2-dose and 3-dose primary rabies vaccination in schoolchildren. Adv Prev Med. 2011;2011:403201 doi:http://dx.doi.org/10.4061/2011/403201 PMID: 21991438
22. Kamoltham T, Thinyounyong W, Phongchamnaphai P, Phraisuwan P, Khawplod P, Banzhoff A, et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr. 2007 Aug;151(2):173-7 doi:http://dx.doi.org/10.1016/j.jpeds.2007.02.044 PMID: 17643772
23. Khawplod P, Wilde H, Sriaroon C, Chomchey P, Kamolthum T, Sitprija V. One or three intradermal injections within one week for rabies pre-exposure immunization. Dev Biol (Basel). 2008;131:393-401. PMID: 18634501
24. Khawplod P, Jaijaroensup W, Sawangvaree A, Prakongsri S, Wilde H. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine. 2012 Apr 19;30(19):2918-20 doi:http://dx.doi.org/10.1016/j.vaccine.2011.12.028 PMID: 22178519
25. Khawplod P, Wilde H, Benjavongkulchai M, Sriaroon C, Chomchey P. Immunogenicity study of abbreviated rabies preexposure vaccination schedules. J Travel Med. 2007 May-Jun;14(3):173-6 doi:http://dx.doi.org/10.1111/j.1708-8305.2007.00120.x PMID: 17437473
26. Lang J, Duong GH, Nguyen VG, Le TT, Nguyen CV, Kesmedjian V, et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet. 1997 Jun 7;349(9066):1663-5 doi:http://dx.doi.org/10.1016/S0140-6736(96)10085-4 PMID: 9186385
27. Lang J, Feroldi E, Vien NC. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam. J Trop Pediatr. 2009 Feb;55(1):26-31 doi:http://dx.doi.org/10.1093/tropej/fmm100 PMID: 18048461
28. Lau CL, Hohl N. Immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule using a purified chick embryo cell vaccine: an observational study. Travel Med Infect Dis. 2013 Nov-Dec;11(6):427-30 doi:http://dx.doi.org/10.1016/j.tmaid.2013.09.006 PMID: 24135254
29. Lim PL, Barkham TM. Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore. Int J Infect Dis. 2010 Jun;14(6):e511-3 doi:http://dx.doi.org/10.1016/j.ijid.2009.08.008 PMID: 20018545
30. Liu Q, Ertl HC. Preventative childhood vaccination to rabies. Expert Opin Biol Ther. 2012 Aug;12(8):1067-75 doi:http://dx.doi.org/10.1517/14712598.2012.691162 PMID: 22724389
31. Lumbiganon P, Chaiprasithikul P, Sookpranee T, Paholpak S, Wasi C. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pac J Allergy Immunol. 1989 Dec;7(2):99-101. PMID: 2624670
32. Malerczyk C, Vakil HB, Bender W. Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV). Hum Vaccin Immunother. 2013 Jul;9(7):1454-9 doi:http://dx.doi.org/10.4161/hv.24502 PMID: 23571224
33. Mills DJ, Lau CL, Fearnley EJ, Weinstein P. The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule-a case series of 420 travelers. J Travel Med. 2011 Sep-Oct;18(5):327-32 doi:http://dx.doi.org/10.1111/j.1708-8305.2011.00540.x PMID: 21896096
34. Pengsaa K, Limkittikul K, Sabchareon A, Ariyasriwatana C, Chanthavanich P, Attanath P, et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12-to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J. 2009 Apr;28(4):335-7 doi:http://dx.doi.org/10.1097/INF.0b013e3181906351 PMID: 19333080
35. Ravish HS, Srikanth J, Ashwath Narayana DH, Annadani R, Vijayashankar V, Undi M. Pre-exposure prophylaxis against rabies in children: safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route. Hum Vaccin Immunother. 2013 Sep;9(9):1910-3 doi:http://dx.doi.org/10.4161/hv.25203 PMID: 23787889
36. Shanbag P, Shah N, Kulkarni M, Juvekar M, Madhusudana SN, Vakil HB, et al. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). Hum Vaccin. 2008 Sep-Oct;4(5):365-9 doi:http://dx.doi.org/10.4161/hv.4.5.5987 PMID: 18398307
37. Strady C, Andreoletti L, Baumard S, Servettaz A, Jaussaud R, Strady A. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans R Soc Trop Med Hyg. 2009 Nov;103(11):1159-64 doi:http://dx.doi.org/10.1016/j.trstmh.2009.03.007 PMID: 19359026
38. Sudarshan MK, Ravish HS, Narayana DHA. Time interval for booster vaccination following re-exposure to rabies in previously vaccinated subjects. Asian Biomed. 2011;5(5):589-93.
39. Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, et al.; Indian Academy of Pediatrics. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years-India, 2014 and updates on immunization. Indian Pediatr. 2014 Oct;51(10):785-800 doi:http://dx.doi.org/10.1007/s13312-014-0504-y PMID: 25362009
40. Vien NC, Feroldi E, Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg. 2008 Mar;102(3):294-6 doi:http://dx.doi.org/10.1016/j.trstmh.2007.11.010 PMID: 18191971
41. Wongsaroj P, Udomchaisakul P, Tepsumethanon S, Khawplod P, Tantawichien T. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis. Vaccine. 2013 Mar 25;31(13):1748-51 doi:http://dx.doi.org/10.1016/j.vaccine.2013.01.035 PMID: 23370149
42. Bernard KW, Fishbein DB. Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost? Vaccine. 1991 Nov;9(11):833-6 doi:http://dx.doi.org/10.1016/0264-410X(91)90221-Q PMID: 1759505
43. Strady C, Hung Nguyen V, Jaussaud R, Lang J, Lienard M, Strady A. Pre-exposure rabies vaccination: strategies and cost-minimization study. Vaccine. 2001 Jan 8;19(11-12):1416-24 doi:http://dx.doi.org/10.1016/S0264-410X(00)00368-6 PMID: 11163664
44. DiStefano D, Antonello JM, Bett AJ, Medi MB, Casimiro DR, ter Meulen J. Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques. Vaccine. 2013 Oct 1;31(42):4888-93 doi:http://dx.doi.org/10.1016/j.vaccine.2013.07.034 PMID: 23941913
45. Hu X, Liu R, Zhu N. Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice. Immunobiology. 2013 Dec;218(12):1524-8 doi:http://dx.doi.org/10.1016/j.imbio.2013.05.006 PMID: 23816301
46. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009 Oct 15;200(8):1251-60 doi:http://dx.doi.org/10.1086/605949 PMID: 19764884
47. Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006 Oct;12(10):1596-9 doi:http://dx.doi.org/10.3201/eid1210.060078 PMID: 17176582
48. Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, et al. Immunogenicity, safety, and tolerability of a recombinant measlesvirus-based chikungunya vaccine: a randomised, double-blind, placebocontrolled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015 May;15(5):519-27 doi:http://dx.doi.org/10.1016/S1473-3099(15)70043-5 PMID: 25739878
49. Rennick LJ, de Vries RD, Carsillo TJ, Lemon K, van Amerongen G, Ludlow M, et al. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. J Virol. 2015 Feb;89(4):2192-200 doi:http://dx.doi.org/10.1128/JVI.02924-14 PMID: 25473055